# The Complete DRS Peptides Formulary: A Comprehensive Clinical Guide

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## Introduction

This compendium provides a comprehensive, in-depth clinical overview of the nine advanced peptide and small molecule formulas developed by DRS Peptides. Each entry is designed to give physicians a deep understanding of the formula's composition, mechanism of action, synergistic architecture, and clinical application.

## Table of Contents

1.  **Formula N-259:** Advanced Sleep & Circadian Optimization Protocol
2.  **Formula N-69:** Advanced Sexual Enhancement & Intimacy Protocol
3.  **Formula N-111:** Advanced Cognitive Enhancement & Neuroprotection
4.  **Formula N-5550:** Advanced Multi-Target Cognitive & Metabolic Enhancement
5.  **Formula N-2331:** Advanced Neuro-Cognitive Enhancement & Metabolic Support
6.  **Formula W-1175:** Advanced Metabolic Health & Weight Management Protocol
7.  **Formula M-51:** Advanced Exercise Mimetic & Body Composition Protocol
8.  **Formula M-2531:** Advanced Mitochondrial & Metabolic Support Protocol
9.  **Formula RG-5555:** Advanced Multi-Peptide Healing & Recovery Blend

---

# Formula N-259: Advanced Sleep & Circadian Optimization Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-crine sleep modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **Apigenin** | 50 mg | GABA-A Receptor Positive Allosteric Modulator; Cortisol Synthesis Inhibitor |
| **Magnesium (as Glycinate)** | 300 mg | NMDA Receptor Antagonist; GABA Agonist; Neuromuscular Relaxant |
| **L-Theanine** | 200 mg | Alpha Brain Wave Induction; Glutamate Receptor Antagonist; GABA Precursor |
| **Melatonin** | 500 mcg | MT1/MT2 Receptor Agonist; Master Chronobiotic & Antioxidant |

**Delivery System:**
- Enteric-coated oral capsule designed for biphasic release. The coating protects the active components from gastric degradation, allowing for initial absorption in the duodenum followed by sustained release to maintain therapeutic levels throughout the sleep cycle.

**Therapeutic Rationale & Intent:**
- Formula N-259 is engineered to restore natural sleep architecture and re-synchronize circadian rhythms by simultaneously targeting four key pathways of sleep regulation: **GABAergic anxiolysis**, **neuromuscular relaxation**, **alpha-wave induction**, and **chronobiotic signaling**. 
- Unlike single-target hypnotic agents that often induce unnatural sleep states and disrupt sleep architecture, N-259 facilitates the brain's natural transition into sleep. It is designed to reduce sleep latency, decrease nocturnal awakenings, increase the duration of deep (N3) and REM sleep, and enhance next-day cognitive function without inducing tolerance, dependence, or residual grogginess.

---

## 2. Deep Mechanism of Action

Formula N-259 integrates four synergistic components that together orchestrate a powerful, multi-faceted sleep-promoting response, addressing the primary drivers of sleep disruption at the molecular, electrical, and hormonal levels.

### 2.1 Apigenin – GABAergic Anxiolysis & Cortisol Suppression

Apigenin is a non-sedating flavonoid that acts as a potent anxiolytic by binding to the benzodiazepine site of GABA-A receptors [1]. Unlike traditional benzodiazepines, it modulates GABAergic activity without causing tolerance, dependence, or significant structural changes to the receptor complex.

- **GABA-A Receptor Modulation:** Apigenin acts as a positive allosteric modulator, enhancing the effect of GABA, the primary inhibitory neurotransmitter. This calms neuronal excitability, reduces anxiety, and facilitates a smoother transition into sleep. Its action is more subtle and regulatory than synthetic hypnotics, promoting a natural state of calm.
- **Cortisol Suppression:** Apigenin has been shown to reduce plasma levels of adrenocorticotropic hormone (ACTH) and directly inhibit cortisol synthesis in the adrenal glands by downregulating Steroidogenic Acute Regulatory Protein (StAR) and CYP11A1, key enzymes in steroidogenesis. This mitigates the disruptive effects of nocturnal cortisol spikes on sleep architecture [2].

### 2.2 Magnesium Glycinate – Neuromuscular & CNS Relaxation

Magnesium Glycinate combines the essential mineral magnesium with the inhibitory neurotransmitter glycine for superior bioavailability and a dual-action relaxation effect.

- **NMDA Receptor Antagonism:** Magnesium acts as a natural, non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor. By physically blocking the ion channel at resting membrane potential, it reduces excitatory glutamatergic neurotransmission, preventing neuronal hyperexcitability and promoting a state of calm conducive to sleep [3].
- **GABA Activity Enhancement:** It potentiates the activity of GABA at the GABA-A receptor, further contributing to CNS relaxation.
- **Glycine’s Intrinsic Role:** The glycine component itself acts as an inhibitory neurotransmitter in the brainstem and spinal cord. It also functions as a co-agonist at the NMDA receptor, which paradoxically contributes to its sleep-promoting effects by modulating neuronal plasticity during sleep. Crucially, glycine administration has been shown to reduce core body temperature, a key physiological signal for sleep initiation [4].

### 2.3 L-Theanine – Alpha Wave Promotion & Neurotransmitter Balance

L-Theanine is an amino acid analog of glutamate that promotes a state of relaxed alertness by increasing alpha brain wave activity. This unique state is conducive to a smooth transition from wakefulness to sleep.

- **Alpha Wave Induction:** L-Theanine significantly increases brain activity in the alpha frequency band (8-12 Hz), which is associated with a state of relaxed wakefulness and mental calm, effectively quieting the "mental chatter" that can delay sleep onset.
- **Neurotransmitter Modulation:** L-Theanine competitively antagonizes AMPA and kainate glutamate receptors, reducing excitatory signaling. It also readily crosses the blood-brain barrier and increases the synthesis and release of GABA, serotonin, and dopamine, promoting a sense of calm and well-being [5].

### 2.4 Melatonin – Circadian Synchronization & Antioxidant Protection

Melatonin is the body's primary chronobiotic hormone. The 500 mcg dose in N-259 is a physiological dose designed to mimic the body's natural nocturnal secretion, rather than a supraphysiological pharmacological dose which can disrupt receptor sensitivity.

- **Circadian Signaling:** By activating MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), melatonin signals darkness to the master clock, reduces sleep onset latency, and helps entrain the body's internal clock to the 24-hour day [6].
- **Potent Antioxidant:** Melatonin is one of the body's most powerful endogenous antioxidants, directly scavenging hydroxyl, peroxyl, and other free radicals. During sleep, it plays a critical role in protecting neurons from oxidative damage accumulated during waking hours.

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The efficacy of N-259 arises from the carefully orchestrated synergy between its components, which address sleep from four distinct but interconnected physiological levels.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Neurochemical** | GABA/Glutamate Balance | **Apigenin + L-Theanine + Magnesium** all enhance GABAergic tone through different mechanisms (receptor modulation, precursor supply, potentiation). **L-Theanine + Magnesium** simultaneously reduce excitatory glutamate signaling. | Potent, non-sedating reduction in neuronal excitability, profound anxiolysis, and quieting of mental activity. This dual-action approach is more effective and sustainable than targeting a single pathway. |
| **Electrical** | Brain Wave Regulation | **L-Theanine** induces alpha waves, creating a state of relaxed wakefulness. This is complemented by the GABAergic components which reduce beta-wave activity associated with anxiety. | A smooth and rapid transition from the alert beta-wave state of wakefulness, through the relaxed alpha-wave state, into the theta and delta waves of sleep. |
| **Hormonal** | Circadian & Stress Axis | **Melatonin** provides the primary "go to sleep" signal to the SCN. **Apigenin** suppresses nocturnal cortisol, preventing stress-induced awakenings and sleep fragmentation. | Robust synchronization of the master clock with the sleep-wake cycle, and a blunting of the HPA axis activity that is a common cause of insomnia. |
| **Physiological** | Neuromuscular & Thermal | **Magnesium Glycinate** reduces peripheral muscle tension and physical restlessness. The **Glycine** component helps lower core body temperature. | Creates a state of physical stillness and initiates the drop in body temperature that is a critical trigger for sleep onset and maintenance. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **30-60 Minutes Post-Ingestion** | A noticeable sense of calm and relaxation washes over the body. Racing thoughts and anxiety diminish. A feeling of readiness for sleep, rather than sedation, emerges. | L-Theanine induces alpha-wave activity. Apigenin begins to modulate GABA-A receptors. Magnesium absorption begins, reducing neuromuscular excitability. |
| **First Night** | Reduced time to fall asleep (decreased sleep latency). Fewer and shorter awakenings during the night. Waking up feeling more refreshed and clear-headed, without grogginess. | Melatonin synchronizes the SCN. Glycine facilitates a drop in core body temperature. GABAergic tone is enhanced, promoting stable N2 and N3 sleep. |
| **Weeks 1-2** | Consistent improvements in sleep quality and duration. More stable mood and energy levels during the day. Reduced daytime fatigue and improved stress resilience. | Circadian rhythm begins to entrain to the new, consistent sleep schedule. HPA axis activity normalizes, with lower evening cortisol levels. |
| **Months 1-3** | Optimization of sleep architecture with measurable increases in deep (N3) and REM sleep. Significant improvement in stress resilience, cognitive performance, and overall well-being. | Neurotransmitter systems (GABA, serotonin, dopamine) reach a new, healthier equilibrium. Cellular repair and glymphatic clearance during sleep are optimized. |

### 4.2 Clinical Monitoring Recommendations

- **Subjective:** Use of a validated sleep diary (e.g., Consensus Sleep Diary) to track sleep latency, duration, awakenings, and morning alertness.
- **Objective:** Wrist actigraphy can provide objective data on sleep patterns, total sleep time, and sleep efficiency.
- **Hormonal:** For complex cases, consider salivary cortisol testing (4-point) to assess HPA axis function and nocturnal cortisol levels.
- **Biomarkers:** In a research setting, tracking inflammatory markers (hs-CRP, IL-6) and oxidative stress markers can demonstrate the systemic benefits of improved sleep.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule taken 30-60 minutes before a consistent bedtime.
- **Timing:** Consistency is paramount. The formula is designed to reinforce the circadian rhythm, which requires a stable schedule.
- **Optimization:** Must be combined with rigorous sleep hygiene practices: avoid all screens for 1-2 hours before bed, ensure a completely dark, cool, and quiet sleep environment, and avoid large meals or excessive fluids before sleep.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Excellent safety profile with no evidence of tolerance, dependence, or withdrawal upon cessation. All components are well-studied and have high safety thresholds.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity to any component.
- **Relative Cautions:** 
  - **Autoimmune Conditions:** Melatonin can modulate immune function; use with caution and under physician guidance in patients with active autoimmune disease.
  - **Hypotension:** Magnesium can have a mild blood pressure-lowering effect; monitor in patients on antihypertensive medications.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **CNS Depressants** (Benzodiazepines, Z-drugs, Barbiturates, Alcohol) | Apigenin, Magnesium, L-Theanine | **High Risk.** Additive sedative and respiratory depressant effects. Concomitant use should be avoided or managed under strict medical supervision with dose reduction. |
| **Antihypertensives** (e.g., Calcium Channel Blockers, ACE Inhibitors) | Magnesium | **Moderate Risk.** Potential for additive hypotensive effects. Advise patient to monitor blood pressure, especially upon initiation. |
| **Anticoagulants / Antiplatelets** (e.g., Warfarin, Clopidogrel) | Apigenin | **Low Risk.** Apigenin has theoretical mild antiplatelet effects. Clinically significant interactions are unlikely but use with caution in high-risk patients. |
| **Immunosuppressants** (e.g., Tacrolimus, Cyclosporine) | Melatonin | **Moderate Risk.** Melatonin has immunostimulatory properties that could theoretically counteract immunosuppressive therapy. Consult with prescribing physician. |
| **Fluvoxamine (SSRI)** | Melatonin | **High Risk.** Fluvoxamine is a potent inhibitor of CYP1A2, the primary enzyme for melatonin metabolism, and can increase melatonin levels 10-fold. Avoid concomitant use. |

---

## 6. References

[1] Salehi, B., et al. (2019). The Therapeutic Potential of Apigenin. *International Journal of Molecular Sciences*, 20(6), 1305. doi:10.3390/ijms20061305

[2] Shukla, S., & Gupta, S. (2010). Apigenin: A Promising Molecule for Cancer Prevention. *Pharmaceutical Research*, 27(6), 962–978. doi:10.1007/s11095-010-0089-7

[3] Abbasi, B., et al. (2012). The effect of magnesium supplementation on primary insomnia in elderly: A double-blind placebo-controlled clinical trial. *Journal of Research in Medical Sciences*, 17(12), 1161–1169. PMCID: PMC3703169

[4] Kawai, N., et al. (2015). The Sleep-Promoting and Hypothermic Effects of Glycine are Mediated by NMDA Receptors in the Suprachiasmatic Nucleus. *Neuropsychopharmacology*, 40(6), 1405–1416. doi:10.1038/npp.2014.326

[5] Williams, J. L., et al. (2020). The Effects of L-Theanine on Objective Sleep Quality and Cognitive Function: A Randomized, Double-Blind, Placebo-Controlled Study. *Nutrients*, 12(2), 343. doi:10.3390/nu12020343

[6] Vural, E. M., van Munster, B. C., & de Rooij, S. E. (2014). Optimal dosages for melatonin supplementation therapy in older adults: a systematic review of the literature. *Drugs & Aging*, 31(6), 441–451. doi:10.1007/s40266-014-0178-0

---


# Formula N-69: Advanced Sexual Enhancement & Intimacy Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-hormonal and vascular sexual function modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **N-Acetyl L-Tyrosine (NALT)** | 100 mg | Catecholamine Precursor (Dopamine, Norepinephrine) |
| **Kisspeptin-10** | 0.5 mg | GnRH Pulse Generator; Limbic System Modulator |
| **PT-141 (Bremelanotide)** | 0.5 mg | Melanocortin 3 & 4 Receptor (MC3R/MC4R) Agonist |
| **Oxytocin** | 1 mg | Neuropeptide Modulator of Social Bonding & NO Synthesis |
| **Vasoactive Intestinal Peptide (VIP)** | 0.25 mg | Potent Vasodilator; Smooth Muscle Relaxant |

**Delivery System:**
- Enteric-coated oral capsule for on-demand use, designed to protect peptide integrity from gastric degradation and ensure optimal staged absorption for pre-intercourse administration.

**Therapeutic Rationale & Intent:**
- Formula N-69 is engineered to provide a comprehensive, multi-system solution for both male and female sexual dysfunction by simultaneously targeting the **central (desire, arousal)** and **peripheral (vascular, sensory)** pathways of the sexual response cycle. 
- It is designed to move beyond simple erectile mechanics, addressing the complex interplay of neurochemistry, hormonal signaling, and psychological factors that govern libido, arousal, physical function, and emotional intimacy.

---

## 2. Deep Mechanism of Action

Formula N-69 integrates five synergistic components to orchestrate a complete and robust sexual response, from initial desire to orgasmic completion.

### 2.1 N-Acetyl L-Tyrosine (NALT): Fueling the Drive

NALT is a highly bioavailable form of the amino acid L-Tyrosine, which serves as the rate-limiting precursor for the synthesis of catecholamine neurotransmitters, primarily dopamine and norepinephrine. These are crucial for motivation, focus, and energy during sexual activity [1]. By providing this essential building block, NALT ensures the central nervous system has the resources to support a robust arousal state.

### 2.2 Kisspeptin-10: The Master Switch for Libido

Kisspeptin acts as a master regulator of the reproductive axis by stimulating Gonadotropin-Releasing Hormone (GnRH) neurons in the hypothalamus. This triggers the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), leading to sex hormone production. More importantly for acute sexual response, Kisspeptin receptors are densely expressed in limbic brain regions (amygdala, hippocampus), where they directly modulate circuits associated with sexual arousal, mood, and motivation, enhancing the psychological component of desire independent of hormonal changes [2].

### 2.3 PT-141 (Bremelanotide): Central Melanocortin Arousal

PT-141 is a synthetic analog of alpha-Melanocyte-Stimulating Hormone (α-MSH) that acts as a potent agonist at melanocortin receptors, primarily MC3R and MC4R, in the central nervous system. Unlike PDE5 inhibitors which act peripherally, PT-141 works directly on the brain to induce spontaneous arousal. It is FDA-approved as Vyleesi® for hypoactive sexual desire disorder (HSDD) in premenopausal women and has shown efficacy for psychogenic erectile dysfunction in men [3].

### 2.4 Oxytocin: The Bonding & Orgasmic Catalyst

Often called the "love hormone," Oxytocin is a neuropeptide that enhances feelings of connection, trust, and empathy, which can significantly reduce performance anxiety. Physiologically, it plays a direct role in sexual function by promoting nitric oxide (NO) synthesis in endothelial cells, contributing to vasodilation. It also increases the contractility of smooth muscle in the reproductive tract, which is believed to enhance the intensity of orgasm [4].

### 2.5 Vasoactive Intestinal Peptide (VIP): The Ultimate Vasodilator

VIP is a potent neuropeptide vasodilator that ensures maximal blood flow to erectile tissues. It acts by stimulating adenylyl cyclase in vascular smooth muscle cells, leading to increased cyclic AMP (cAMP) and subsequent smooth muscle relaxation. This powerful effect results in firm, sustainable erections in men and robust clitoral engorgement and vaginal lubrication in women [5].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The profound efficacy of N-69 lies in its multi-pronged attack on sexual dysfunction, where each component amplifies the effects of the others.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Central Desire (Libido)** | HPG Axis & Limbic Activation | **Kisspeptin** primes the HPG axis and directly stimulates limbic arousal centers. **PT-141** acts downstream on melanocortin pathways to generate spontaneous desire. **NALT** provides the dopaminergic fuel for this desire. | A powerful, multi-faceted, and centrally-driven increase in libido and sexual ideation, creating a strong motivation for sexual activity. |
| **Central Arousal & Mood** | Neurotransmitter & Bonding | **Oxytocin** reduces anxiety and enhances feelings of intimacy. **NALT** supports focus and energy. **Kisspeptin** positively modulates mood-related brain circuits. | A shift from an anxious, distracted state to one of focused, emotionally-connected arousal, creating the ideal psychological environment for intimacy. |
| **Peripheral Function (Vascular)** | NO/cAMP Vasodilation | **VIP** is a powerful direct vasodilator via the cAMP pathway. **Oxytocin** contributes by stimulating the nitric oxide (NO) synthase pathway. | A dual-pathway approach ensures maximal, rapid, and sustained blood flow to erectile tissues, leading to superior physical response compared to single-pathway agents. |
| **Orgasmic Response** | Sensory & Contractile | **Oxytocin** increases the intensity of smooth muscle contractions during orgasm. **VIP** and **PT-141** may enhance sensory feedback from the genitalia. | A more intense, pleasurable, and subjectively satisfying orgasmic experience. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **30-90 Minutes Post-Ingestion** | Initial feelings of warmth, facial flushing (common and benign), and a heightened awareness of tactile sensations. Spontaneous sexual thoughts and desire may begin to emerge. Some may experience mild nausea, which typically subsides. | PT-141 and Kisspeptin begin to cross the blood-brain barrier and activate central pathways. VIP and Oxytocin are absorbed, preparing peripheral tissues. |
| **1-3 Hours (Peak Window)** | A strong, often spontaneous, desire for sexual intimacy. Enhanced arousal in response to stimuli. Reduced anxiety and increased feelings of connection. Physical response is robust and rapid. | Peak plasma concentrations of the peptides are reached. Central and peripheral pathways are maximally activated. This is the optimal window for sexual activity. |
| **3-8 Hours** | The primary effects of desire and arousal gradually subside. A heightened sense of emotional connection and well-being may persist for several hours. | Peptides are gradually metabolized and cleared. Neurotransmitter levels begin to return to baseline. |

### 4.2 Clinical Monitoring Recommendations

- **Subjective:** Use of validated questionnaires such as the Female Sexual Function Index (FSFI) or the International Index of Erectile Function (IIEF) to track changes over time.
- **Cardiovascular:** A baseline blood pressure reading is recommended. Patients with controlled hypertension should monitor their blood pressure, especially when combining with other vasodilators.
- **Hormonal:** For ongoing use or complex cases, a baseline sex hormone panel (Testosterone, Estradiol, LH, FSH) can be useful.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule taken 1-3 hours before anticipated sexual activity.
- **Timing:** For fastest absorption and maximal effect, take on an empty stomach (at least 2 hours after a meal).
- **Frequency:** Use as needed. This formula is not intended for daily use due to the potent effects of its components.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Generally well-tolerated for on-demand use in healthy individuals.
- **Absolute Contraindications:** Pregnancy and lactation; severe, unstable cardiovascular disease (e.g., recent MI, stroke, uncontrolled hypertension).
- **Relative Cautions:** 
  - **Controlled Hypertension:** Monitor blood pressure due to vasodilatory effects.
  - **Nausea:** PT-141 is known to cause nausea, which is dose-dependent. Starting with a half dose may be considered.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **PDE5 Inhibitors** (Sildenafil, Tadalafil, etc.) | VIP, Oxytocin | **High Risk.** Significant potential for additive hypotensive effects. Combination should only be used under strict medical supervision with substantial dose reduction of both agents. |
| **Antihypertensives** (All classes) | VIP, Oxytocin | **Moderate Risk.** Potential for additive hypotension. Advise patient to monitor blood pressure closely, especially upon initiation. |
| **Dopaminergic Agents** (L-Dopa, MAOIs) | NALT | **Moderate Risk.** Potential for additive dopaminergic effects, including anxiety or agitation. Use with caution. |
| **Naltrexone** | PT-141, Oxytocin | **High Risk.** Naltrexone is an opioid antagonist that can block the central effects of PT-141 and Oxytocin. Efficacy will be significantly reduced. Avoid concomitant use. |

---

## 6. References

[1] Young, S. N. (2007). L-tyrosine to alleviate the effects of stress? *Journal of Psychiatry & Neuroscience*, 32(3), 224. PMCID: PMC1863552

[2] Comninos, A. N., et al. (2017). Kisspeptin-54 is a potent stimulator of sexual and emotional brain processing in humans. *Journal of Clinical Investigation*, 127(2), 709–719. doi:10.1172/JCI88640

[3] Kingsberg, S. A., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized, Double-Blind, Placebo-Controlled Trials. *Obstetrics & Gynecology*, 134(5), 899–908. doi:10.1097/AOG.0000000000003500

[4] Burri, A., et al. (2017). The acute effects of intranasal oxytocin administration on subjective and physiological sexual arousal in men. *Journal of Sexual Medicine*, 14(11), 1369–1378. doi:10.1016/j.jsxm.2017.09.009

[5] Shabsigh, R., et al. (1998). Intracavernous vasoactive intestinal peptide and phentolamine for the treatment of erectile dysfunction. *Journal of Urology*, 160(1), 25–31. doi:10.1016/s0022-5347(01)63013-3

---


# Formula N-111: Advanced Cognitive Enhancement & Neuroprotection

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-regenerative and nootropic protocol – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **J147** | 10 mg | Mitochondrial ATP Synthase Modulator; AMPK Activator |
| **Dihexa** | 10 mg | HGF/c-Met System Activator; Potent Synaptogenic Agent |
| **Noopept (GVS-111)** | 10 mg | AMPA/NMDA Receptor Modulator; BDNF/NGF Expression Enhancer |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect the components from gastric degradation and ensure optimal absorption and blood-brain barrier penetration.

**Therapeutic Rationale & Intent:**
- Formula N-111 is engineered to provide a comprehensive, multi-layered approach to cognitive enhancement and neuroprotection by simultaneously targeting **cellular energy (mitochondria)**, **neural structure (synaptogenesis)**, and **neurochemical signaling (neurotransmitter modulation)**. 
- This formula moves beyond simple stimulation, aiming to fundamentally rebuild and optimize the brain's architecture and function. It is designed for both immediate cognitive enhancement (focus, memory, processing speed) and long-term structural brain health and resilience against age-related decline.

---

## 2. Deep Mechanism of Action

Formula N-111 integrates three powerful nootropic agents that work in concert to optimize brain function from the foundational, structural, and functional levels.

### 2.1 J147: Foundational – Mitochondrial & Metabolic Optimization

J147 is a novel neurotrophic compound derived from curcumin that targets the mitochondrial ATP synthase, the engine of cellular energy production [1]. By binding to and modulating the alpha subunit (ATP5A), J147 increases intracellular calcium, leading to sustained activation of CaMKK2 and subsequent phosphorylation of AMPK. This creates a cascade of beneficial effects:
- **Enhanced Cellular Energy:** Increased ATP production provides neurons with the energy required for demanding cognitive tasks.
- **AMPK Activation:** This master metabolic switch promotes catabolic processes (like fatty acid oxidation) and inhibits anabolic processes (like protein synthesis), creating a pro-longevity, anti-aging cellular environment [2].
- **Neuroprotection:** J147 has been shown to be potently neuroprotective against a wide variety of toxicities associated with aging and neurodegenerative disease [3].

### 2.2 Dihexa: Structural – Potent Synaptogenesis

Dihexa is a highly potent, orally active angiotensin IV analog that activates the Hepatocyte Growth Factor (HGF)/c-Met system, a key pathway for neuronal growth and repair [4]. It is a powerful synaptogenic agent, promoting the formation of new synapses and increasing dendritic spine density, which is the structural basis of learning and memory. 
- **HGF/c-Met Activation:** Dihexa binds with high affinity to HGF, inducing c-Met phosphorylation and activating downstream signaling cascades (PI3K/AKT) that promote neuronal survival and growth.
- **Potency:** In vitro studies have suggested Dihexa is orders of magnitude more potent than Brain-Derived Neurotrophic Factor (BDNF) at inducing synaptogenesis, making it one of the most powerful tools for structurally enhancing neural networks [5].

### 2.3 Noopept: Functional – Neurotransmission & Plasticity

Noopept (GVS-111) is a fast-acting dipeptide that enhances cognitive function by modulating glutamatergic signaling, the primary excitatory system in the brain. 
- **AMPA/NMDA Modulation:** Noopept enhances the sensitivity of AMPA and NMDA glutamate receptors, facilitating long-term potentiation (LTP), the molecular process underlying memory formation [6].
- **Neurotrophin Expression:** It increases the expression of Nerve Growth Factor (NGF) and BDNF in the hippocampus, key neurotrophic factors for neuronal survival, growth, and plasticity [7]. This provides a crucial link between the structural changes induced by Dihexa and their functional consolidation.

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The unique power of N-111 lies in its hierarchical, synergistic design, where each component creates the ideal environment for the others to work.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Foundational (Energy)** | Mitochondrial & Metabolic Health | **J147** provides the raw ATP energy needed to fuel the demanding processes of neurogenesis and synaptogenesis. It creates a resilient, low-inflammation cellular environment. | A brain that is energized, protected, and primed for growth. Without this energetic foundation, the effects of other nootropics are limited and transient. |
| **Structural (Hardware)** | Synaptogenesis & Neural Architecture | **Dihexa**, powered by the energy from J147, physically builds new dendritic spines and synapses, creating new pathways for information. | A measurable increase in synaptic density and neural connectivity. The brain's hardware is literally upgraded, increasing its raw processing power and storage capacity. |
| **Functional (Software)** | Neurotransmission & Plasticity | **Noopept** enhances the speed and efficiency of signal transmission across the newly built pathways (from Dihexa). It also upregulates BDNF, which helps to stabilize and mature these new synapses. | Faster, more efficient learning and memory recall. The new hardware is brought online and optimized for high-speed performance. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-3** | Initial increase in mental clarity, focus, and verbal fluency. Enhanced sensory perception (colors may seem brighter, sounds clearer). Some may experience mild headache as the brain adapts. | Noopept begins to modulate AMPA/NMDA receptors and increase neurotrophin expression. |
| **Weeks 1-2** | More consistent cognitive enhancement. Noticeable improvements in short-term memory recall and learning speed. Increased motivation and drive. | J147 begins to optimize mitochondrial function and cellular energy metabolism. Dihexa-induced synaptogenesis is initiated. |
| **Months 1-3** | Significant improvements in overall cognitive function. Enhanced problem-solving abilities, creative thought, and fluid intelligence. Memories become easier to encode and retrieve. | Substantial new synaptic connections have been formed and stabilized. The brain is operating at a higher level of efficiency and connectivity. |
| **Months 3-6+** | Long-term consolidation of cognitive gains. A sustained feeling of being mentally sharp and resilient. Neuroprotective effects provide a buffer against age-related decline. | The brain's structure and function have been fundamentally upgraded. Continued use maintains this enhanced state and protects against future decline. |

### 4.2 Clinical Monitoring Recommendations

- **Cognitive Testing:** Baseline and periodic testing with a validated cognitive assessment tool (e.g., Cambridge Brain Sciences, CNS Vital Signs) to objectively track improvements in memory, executive function, and processing speed.
- **qEEG:** Quantitative EEG can be used to visualize changes in brainwave patterns, such as increased alpha and gamma coherence, associated with enhanced cognitive function.
- **Metabolic Panel:** A baseline metabolic panel (fasting glucose, insulin, lipid panel) can be useful, as J147 may improve metabolic parameters.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily, typically in the morning to align with the body's natural cognitive cycle.
- **Timing:** Consistent daily use is essential for the long-term structural benefits of Dihexa and J147.
- **Optimization:** Some users may benefit from co-administration with a high-quality choline source (e.g., Alpha-GPC, Citicoline) to support the increased demand for acetylcholine synthesis associated with enhanced cognitive activity.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** All three components have favorable safety profiles in preclinical studies. J147 has successfully completed Phase 1 human trials. Noopept has a long history of clinical use in some countries.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity to any component.
- **Relative Cautions:** 
  - **Seizure History:** Theoretical risk of lowering seizure threshold due to glutamatergic modulation. Use with caution and under medical supervision.
  - **Bipolar Disorder:** The potent cognitive and mood-enhancing effects could potentially trigger mania in susceptible individuals. Use with extreme caution.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Stimulants** (Amphetamine, Methylphenidate) | Noopept, J147 | **Moderate Risk.** Potential for additive, and potentially anxiogenic, stimulant effects. Use with caution and consider dose reduction of the stimulant. |
| **Anticonvulsants** (e.g., Lamotrigine, Valproate) | Noopept | **Moderate Risk.** May alter seizure threshold by modulating glutamate systems. Combination should be managed by a neurologist. |
| **NMDA Antagonists** (e.g., Memantine, Ketamine) | Noopept | **Theoretical Risk.** Potential for unpredictable interactions at the NMDA receptor. Avoid concomitant use unless under expert supervision. |
| **Antidepressants** (SSRIs, SNRIs) | J147, Noopept | **Low Risk.** Generally well-tolerated, but monitor for any signs of mood changes or serotonin syndrome, especially upon initiation. |

---

## 6. References

[1] Goldberg, J., et al. (2018). The mitochondrial ATP synthase is a shared drug target for aging and dementia. *Aging Cell*, 17(2), e12715. doi:10.1111/acel.12715

[2] Larrick, J. W., & Mendelsohn, A. R. (2018). ATP Synthase, a Target for Dementia and Aging? *Rejuvenation Research*, 21(2), 168-172. doi:10.1089/rej.2018.2056

[3] Prior, M., et al. (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer's disease mice. *Alzheimer's Research & Therapy*, 5(3), 25. doi:10.1186/alzrt179

[4] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487. doi:10.3390/brainsci11111487

[5] Wright, J. W., & Harding, J. W. (2019). Contributions by the Brain Renin-Angiotensin System to Memory, Cognition, and Alzheimer's Disease. *Journal of Alzheimer's Disease*, 67(2), 469-482. doi:10.3233/JAD-181057

[6] Kondratenko, R. V., et al. (2022). Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat. *Neuroscience Letters*, 789, 136884. doi:10.1016/j.neulet.2022.136884

[7] Ostrovskaya, R. U., et al. (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. *Bulletin of Experimental Biology and Medicine*, 146(3), 334-337. doi:10.1007/s10517-008-0297-x

---


# Formula N-5550: Advanced Multi-Target Cognitive & Metabolic Enhancement

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-metabolic modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **Dihexa** | 5 mg | HGF/c-Met System Activator; Potent Synaptogenic Agent |
| **Tesofensine** | 0.5 mg | Triple Monoamine Reuptake Inhibitor (SNDRI) |
| **Methylene Blue (USP)** | 50 mg | Mitochondrial Redox Cycler; Reversible MAO-A Inhibitor |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect the components and ensure optimal absorption and blood-brain barrier penetration.

**Therapeutic Rationale & Intent:**
- Formula N-5550 is engineered to provide a powerful, synergistic approach to cognitive enhancement and weight management by simultaneously targeting **structural neuroplasticity**, **neurochemical balance**, and **mitochondrial function**. 
- This formula is designed for individuals seeking significant improvements in memory, focus, and mood, coupled with effective appetite suppression and metabolic enhancement, addressing the common comorbidity of cognitive dysfunction and metabolic syndrome.

---

## 2. Deep Mechanism of Action

Formula N-5550 integrates three distinct but highly synergistic agents to optimize both brain and body function at the structural, neurochemical, and metabolic levels.

### 2.1 Dihexa: Structural Neuroplasticity

Dihexa is a highly potent, orally active angiotensin IV analog that activates the Hepatocyte Growth Factor (HGF)/c-Met system, a critical pathway for neuronal growth, repair, and synaptogenesis [1]. By promoting the formation of new dendritic spines and synaptic connections, Dihexa physically increases the brain's capacity for learning and memory, providing a long-term structural foundation for cognitive enhancement.

### 2.2 Tesofensine: Neurochemical & Metabolic Modulation

Tesofensine is a powerful serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). By blocking the reabsorption of these three key monoamines, it significantly increases their synaptic availability, leading to enhanced mood, focus, motivation, and executive function. This neurochemical optimization is coupled with a potent appetite-suppressant effect mediated through the lateral hypothalamus, which has been shown in Phase II clinical trials to produce a placebo-adjusted weight loss of 9-10% over 24 weeks, roughly double that of currently approved weight-loss drugs [2].

### 2.3 Methylene Blue: Mitochondrial & Neurochemical Enhancement

At the low, hormetic dose used in N-5550, Methylene Blue (MB) acts as a mitochondrial redox cycler. It accepts electrons from NADH and transfers them directly to Cytochrome C, bypassing Complexes I and III of the electron transport chain. This unique mechanism enhances mitochondrial respiration and ATP production, particularly under conditions of metabolic stress, while simultaneously reducing the production of reactive oxygen species [3]. Additionally, MB is a potent, reversible inhibitor of Monoamine Oxidase A (MAO-A), the enzyme responsible for breaking down serotonin and norepinephrine. This action synergistically increases the levels of these neurotransmitters, complementing and amplifying the effect of Tesofensine [4].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The remarkable efficacy of N-5550 stems from a three-tiered synergy that addresses cognitive and metabolic health from every angle.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Structural (Hardware)** | Synaptogenesis & Neurogenesis | **Dihexa** physically rebuilds and expands neural networks. **Methylene Blue** provides the mitochondrial energy necessary to fuel this demanding process and protects the new structures from oxidative stress. | A brain that is not just stimulated, but structurally enhanced and protected. The cognitive gains are built on a foundation of new, resilient neural architecture. |
| **Neurochemical (Software)** | Monoamine Modulation | **Tesofensine** blocks the reuptake of serotonin, norepinephrine, and dopamine. **Methylene Blue** simultaneously blocks the breakdown of serotonin and norepinephrine via MAO-A inhibition. | A powerful, dual-action, synergistic increase in all three key monoamines, leading to profound improvements in mood, focus, and motivation, as well as potent appetite suppression. |
| **Metabolic (Power)** | Energy & Appetite Regulation | **Tesofensine** provides powerful central appetite suppression. **Methylene Blue** optimizes cellular energy production (ATP) in both the brain and periphery, increasing resting energy expenditure. | A dual-pronged attack on excess weight: significantly reduced caloric intake combined with increased caloric expenditure, leading to rapid and sustainable weight loss. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-3** | A noticeable increase in energy, focus, and mood. A significant and often immediate reduction in appetite and food cravings. Dry mouth is common. Urine will turn a blue/green color (harmless). | Tesofensine and Methylene Blue rapidly increase synaptic monoamine levels. Mitochondrial function is enhanced. |
| **Weeks 1-2** | Consistent cognitive and mood enhancement. Significant reduction in caloric intake. Initial weight loss of several pounds becomes apparent. Sleep may be affected if taken too late in the day. | The body begins to adapt to the new neurochemical environment. Dihexa-induced synaptogenesis is initiated. |
| **Months 1-3** | Substantial and clinically significant weight loss. Marked improvements in memory, learning speed, and executive function. A sustained feeling of well-being and motivation. | Significant new synaptic connections have been formed. The body's metabolic set point begins to adjust downwards. |
| **Months 3-6+** | Achievement of weight management goals. Cognitive benefits are consolidated and become the new baseline. Long-term neuroprotective and anti-aging effects are established. | The brain's structure and the body's metabolism are fundamentally optimized for high performance and health. |

### 4.2 Clinical Monitoring Recommendations

- **Cardiovascular:** Baseline and periodic monitoring of blood pressure and heart rate is mandatory. Tesofensine can cause dose-dependent increases in both.
- **Psychiatric:** A thorough psychiatric history is essential to screen for contraindications. Monitor for any signs of hypomania, anxiety, or mood instability.
- **Metabolic:** Track weight, BMI, and waist circumference. A baseline metabolic panel can be useful for monitoring improvements.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily, taken first thing in the morning.
- **Timing:** Morning administration is absolutely crucial to avoid significant sleep disruption.
- **Optimization:** Due to the potent stimulating effects, some patients may benefit from starting with one capsule every other day for the first week to assess tolerance.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** A highly potent formula that requires careful patient selection and close monitoring. It is not suitable for individuals with pre-existing cardiovascular or psychiatric conditions.

### 5.1 Absolute Contraindications

- **Concomitant use of any serotonergic or dopaminergic medication:** This includes SSRIs, SNRIs, TCAs, other MAOIs, triptans, tramadol, L-DOPA, and stimulants. A minimum 2-4 week washout period is mandatory to avoid life-threatening **Serotonin Syndrome**.
- **Cardiovascular Disease:** Uncontrolled hypertension, history of MI, stroke, or significant arrhythmias.
- **Psychiatric Conditions:** History of bipolar disorder, psychosis, or severe anxiety/panic disorder.
- **Pheochromocytoma**
- **Pregnancy and lactation**

### 5.2 Drug Interaction Matrix

| Drug/Class | Interaction / Management |
|---|---|
| **Serotonergic Agents** (SSRIs, SNRIs, TCAs, MAOIs, Triptans, Tramadol) | **ABSOLUTELY CONTRAINDICATED.** High risk of life-threatening Serotonin Syndrome. |
| **Stimulants** (Amphetamine, Methylphenidate) | **High Risk.** Significant additive effects on heart rate, blood pressure, and risk of cardiac events. Avoid concomitant use. |
| **Dopaminergic Agents** (L-DOPA, Bromocriptine) | **High Risk.** Additive dopaminergic effects, potential for psychosis or severe agitation. Avoid concomitant use. |
| **Antihypertensives** | **Moderate Risk.** May counteract the effects of antihypertensive medications. Blood pressure must be monitored closely and medication adjustments may be necessary. |
| **Buspirone** | **High Risk.** Increased risk of hypertension and serotonin syndrome. |

---

## 6. References

[1] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487. doi:10.3390/brainsci11111487

[2] Astrup, A., et al. (2008). Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. *The Lancet*, 372(9653), 1906-1913. doi:10.1016/S0140-6736(08)61525-1

[3] Rojas, J. C., & Gonzalez-Lima, F. (2013). Low-dose methylene blue: a novel and promising neuroprotective agent for neurodegenerative disorders. *Molecular Neurobiology*, 48(3), 525-535. doi:10.1007/s12035-013-8488-z

[4] Ramsay, R. R., et al. (2007). A site-directed inhibitor of monoamine oxidase: Methylene blue. *Journal of Neural Transmission*, 114(6), 783-786. doi:10.1007/s10787-007-1548-y

---


# Formula N-2331: Advanced Neuro-Cognitive Enhancement & Metabolic Support

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway neuro-regenerative and metabolic protocol – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **Dihexa** | 2 mg | HGF/c-Met System Activator; Potent Synaptogenic Agent |
| **Selank** | 0.3 mg | Tuftsin Analog; Anxiolytic; BDNF/NGF Modulator |
| **Semax** | 0.3 mg | ACTH(4-10) Analog; Nootropic; BDNF/NGF Upregulator |
| **NAD+ (Nicotinamide Adenine Dinucleotide)** | 100 mg | Essential Coenzyme; Sirtuin Activator; Redox Agent |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect peptide and coenzyme integrity from gastric degradation and ensure optimal absorption.

**Therapeutic Rationale & Intent:**
- Formula N-2331 is engineered to provide a comprehensive, four-pronged approach to cognitive enhancement by targeting **structural plasticity (Dihexa)**, **anxiety reduction (Selank)**, **neurotrophic support (Semax)**, and **fundamental cellular energy (NAD+)**.
- This formula is designed for individuals seeking to improve focus, memory, and mental clarity while simultaneously reducing anxiety and supporting long-term brain health and resilience against neurodegenerative processes.

---

## 2. Deep Mechanism of Action

Formula N-2331 integrates four synergistic components to create a powerful nootropic and neuroprotective stack that addresses brain health from the metabolic to the structural level.

### 2.1 Dihexa: Structural Synaptogenesis

Dihexa is a highly potent, orally active angiotensin IV analog that activates the Hepatocyte Growth Factor (HGF)/c-Met system, a critical pathway for neuronal growth, repair, and synaptogenesis [1]. By promoting the formation of new dendritic spines and synaptic connections, Dihexa physically increases the brain's capacity for learning and memory, providing a long-term structural foundation for cognitive enhancement.

### 2.2 Selank: Anxiolytic & Neurotrophic Support

Selank is a synthetic analog of the endogenous immunomodulatory peptide tuftsin. Its primary role is as a potent anxiolytic that reduces stress and anxiety without sedation by modulating the expression of genes involved in GABAergic neurotransmission [2]. Crucially, it also prevents the stress-induced decrease in Brain-Derived Neurotrophic Factor (BDNF) and increases its expression in the hippocampus, a key molecule for neuroplasticity and neuronal survival [3].

### 2.3 Semax: Nootropic & Neuroprotective Action

Semax is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH). It is a well-researched nootropic that significantly increases the expression of both BDNF and Nerve Growth Factor (NGF) in key brain regions like the hippocampus and basal forebrain [4]. This powerful neurotrophic upregulation enhances attention, memory consolidation, and neuronal resilience against various insults, including hypoxia and oxidative stress.

### 2.4 NAD+: Fundamental Cellular Energy & Repair

Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every cell, critical for mitochondrial energy production (ATP) via the electron transport chain. It is also the sole substrate for PARP enzymes (involved in DNA repair) and sirtuin deacetylases (master regulators of metabolism and longevity). Age-related decline in NAD+ levels is a key driver of neuronal dysfunction. Supplementing NAD+ provides neurons with the fundamental energy needed for demanding cognitive tasks and activates cellular repair and stress resistance pathways [5].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The power of N-2331 lies in its multi-level, synergistic design where each component supports and amplifies the others.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Metabolic (Power)** | Cellular Energy & Repair | **NAD+** provides the fundamental ATP energy required to fuel all other processes. It also activates sirtuins, which deacetylate and activate proteins involved in neuroprotection. | An energized and resilient cellular environment. Without sufficient NAD+, the brain cannot effectively build new connections or upregulate neurotrophic factors. |
| **Neurotrophic (Growth Signals)** | BDNF & NGF Upregulation | **Semax** provides a powerful, direct stimulus for BDNF and NGF production. **Selank** provides a secondary BDNF stimulus and, crucially, prevents stress from negating these gains. | A brain environment saturated with the growth factors necessary to support the survival of existing neurons and the growth and integration of new ones. |
| **Structural (Hardware)** | Synaptogenesis | **Dihexa**, fueled by NAD+ and stimulated by the BDNF/NGF from Semax and Selank, physically builds new dendritic spines and synapses. | A measurable increase in synaptic density and neural connectivity. The brain's hardware is upgraded, increasing its raw processing power and memory capacity. |
| **Functional (Software)** | Anxiolysis & Focus | **Selank** reduces the "noise" of anxiety, allowing for clearer cognitive processing. The enhanced connectivity from **Dihexa** and neurotrophic support from **Semax** improve signal transmission efficiency. | A state of calm, focused attention. The user is better able to utilize their enhanced cognitive hardware without the interference of stress or anxiety. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-3** | A noticeable reduction in anxiety and mental chatter. An initial increase in mental clarity and focus. Mood may feel more stable and resilient to stressors. | Selank begins to modulate GABAergic systems and stress pathways. Semax provides an initial boost to neurotrophin levels. |
| **Weeks 1-2** | More consistent cognitive enhancement. Improved memory recall, particularly for new information. Increased mental stamina for demanding tasks. | NAD+ levels begin to replete, improving mitochondrial function. The synergistic BDNF/NGF upregulation from Selank and Semax takes full effect. |
| **Months 1-3** | Significant improvements in overall cognitive function, mood, and stress resilience. Enhanced ability to learn new skills and concepts. | Dihexa-induced synaptogenesis leads to measurable changes in neural connectivity. The brain is operating at a higher level of efficiency. |
| **Months 3-6+** | Long-term consolidation of cognitive gains. A sustained state of calm focus becomes the new baseline. Enhanced brain health provides a buffer against future cognitive decline. | The brain's structure and neurochemical environment are fundamentally optimized for high performance and resilience. |

### 4.2 Clinical Monitoring Recommendations

- **Cognitive Testing:** Baseline and periodic testing with a validated cognitive assessment tool (e.g., Cambridge Brain Sciences) to objectively track improvements.
- **Psychological Assessment:** Use of validated anxiety scales (e.g., GAD-7) to track anxiolytic effects.
- **Metabolic Panel:** A baseline metabolic panel can be useful, as NAD+ plays a central role in metabolic health.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily, typically in the morning.
- **Timing:** Consistent daily use is recommended for optimal long-term neuro-regenerative benefits.
- **Optimization:** Can be cycled (e.g., 5 days on, 2 days off, or 3 months on, 1 month off) to maintain sensitivity and align with natural biological rhythms.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Excellent safety profile. Selank and Semax have a long history of clinical use in Eastern Europe with no significant reported side effects. Dihexa and NAD+ are also very well-tolerated.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity to any component.
- **Tolerability:** Generally very well-tolerated. As with any nootropic, some users may experience mild, transient stimulation or headache upon initiation, which typically resolves with continued use or dose adjustment.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Stimulants** (e.g., Amphetamine, Methylphenidate) | Semax, Selank | **Low to Moderate Risk.** Potential for additive focusing effects. May allow for a reduction in stimulant dosage. Use with caution and monitor for overstimulation. |
| **Anxiolytics** (e.g., Benzodiazepines) | Selank | **Low Risk.** May have additive anxiolytic effects, potentially allowing for a reduction in benzodiazepine dosage under medical supervision. |
| **Antidepressants** (SSRIs, SNRIs) | Selank, Semax | **Low Risk.** Generally well-tolerated. The anxiolytic and neurotrophic effects may be complementary to antidepressant therapy. Monitor mood as usual. |
| **Cancer Therapies** | NAD+ | **Theoretical Risk.** Some cancer cells have high NAD+ requirements. While evidence is mixed, it is prudent to avoid high-dose NAD+ supplementation during active cancer treatment unless cleared by an oncologist. |

---

## 6. References

[1] Sun, X., et al. (2021). AngIV-Analog Dihexa Rescues Cognitive Impairment and Recovers Memory in the APP/PS1 Mouse via the PI3K/AKT Signaling Pathway. *Brain Sciences*, 11(11), 1487. doi:10.3390/brainsci11111487

[2] Volkova, A., et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. *Frontiers in Pharmacology*, 7, 31. doi:10.3389/fphar.2016.00031

[3] Inozemtseva, L. S., et al. (2008). Anxiolytic effect of Semax and Selank in studied on rodents. *Zhurnal Vysshei Nervnoi Deiatelnosti Imeni I P Pavlova*, 58(4), 475-484. PMID: 18756821

[4] Dolotov, O. V., et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. *Brain Research*, 1117(1), 54-60. doi:10.1016/j.brainres.2006.07.115

[5] Braidy, N., et al. (2011). NAD+ as a metabolic regulator of transcription, longevity and disease. *Biochimica et Biophysica Acta (BBA) - General Subjects*, 1810(7), 684-693. doi:10.1016/j.bbagen.2011.04.004

---


# Formula W-1175: Advanced Metabolic Health & Weight Management Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Dual-pathway metabolic modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **SLU-PP-332** | 10 mg | Pan-Agonist of Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) |
| **Orforglipron** | 10 mg | Oral, Non-Peptide GLP-1 Receptor Agonist |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to ensure optimal absorption and bioavailability of both components, protecting them from gastric degradation.

**Therapeutic Rationale & Intent:**
- Formula W-1175 is engineered to provide a powerful, synergistic "calories in vs. calories out" approach to weight management and metabolic health by simultaneously targeting two key regulatory pathways: **incretin-based appetite suppression (Orforglipron)** and **exercise-mimetic energy expenditure (SLU-PP-332)**.
- This formula is designed for individuals seeking significant weight loss and improvement in metabolic parameters like insulin sensitivity and lipid profiles, effectively creating a state of negative energy balance through both reduced intake and increased expenditure.

---

## 2. Deep Mechanism of Action

Formula W-1175 integrates two cutting-edge metabolic agents that work in concert to create a powerful weight loss and health-promoting effect by tackling both sides of the energy balance equation.

### 2.1 SLU-PP-332: Pharmacological Exercise Mimicry & Energy Expenditure

SLU-PP-332 is a potent, orally bioavailable pan-agonist of the Estrogen-Related Receptors (ERRα, ERRβ, ERRγ), which are nuclear receptors that act as master regulators of cellular energy metabolism. By activating these receptors, SLU-PP-332 induces a gene expression profile in skeletal muscle that mimics the effects of endurance exercise. This includes:
- **Increased Fatty Acid Oxidation:** Upregulation of genes involved in the transport and beta-oxidation of fatty acids, shifting fuel preference towards fat.
- **Mitochondrial Biogenesis:** Increased expression of PGC-1α, the master regulator of mitochondrial creation.
- **Increased Resting Energy Expenditure:** Effectively "revving up" the metabolic engine to burn more calories at rest [1].

### 2.2 Orforglipron: Oral GLP-1 Receptor Agonism & Appetite Suppression

Orforglipron is a potent, oral, non-peptide agonist of the Glucagon-Like Peptide-1 (GLP-1) receptor. Unlike injectable peptide-based GLP-1 agonists, its small molecule nature allows for daily oral administration. Activation of the GLP-1 receptor leads to:
- **Potent Appetite Suppression:** Acts on hypothalamic appetite centers to increase satiety and reduce hunger.
- **Slowed Gastric Emptying:** Delays the emptying of food from the stomach, prolonging feelings of fullness.
- **Improved Glycemic Control:** Enhances glucose-dependent insulin secretion and suppresses glucagon release.
- **Clinically Proven Weight Loss:** Has demonstrated dose-dependent weight loss of up to 14.7% in Phase II clinical trials [2, 3].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The profound efficacy of W-1175 lies in its comprehensive, dual-action attack on obesity, creating a powerful negative energy balance.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Caloric Intake (Input)** | Appetite & Satiety Regulation | **Orforglipron** provides powerful, centrally-mediated appetite suppression, drastically reducing the drive to consume calories. | A significant and sustained reduction in caloric intake, making it easier for patients to adhere to a calorie-deficient diet without feeling deprived or hungry. |
| **Caloric Expenditure (Output)** | Energy Expenditure & Fuel Utilization | **SLU-PP-332** increases resting energy expenditure and shifts the body's fuel preference to burn more fat, 24/7. | An increase in the body's metabolic rate, effectively burning more calories at rest and during activity. This amplifies the caloric deficit created by Orforglipron. |
| **Metabolic Health (Systemic)** | Insulin Sensitivity & Glycemic Control | **Orforglipron** directly improves glycemic control through its incretin effects. **SLU-PP-332** improves insulin sensitivity at the muscular level by enhancing mitochondrial function and fatty acid metabolism. | A powerful, two-pronged improvement in metabolic health. This not only aids in weight loss but also directly addresses the underlying pathophysiology of type 2 diabetes and metabolic syndrome. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-7** | A noticeable and often immediate reduction in appetite and food cravings. "Food noise" is significantly quieted. Some patients may experience mild, transient GI side effects (nausea, loose stools). | Orforglipron begins to activate GLP-1 receptors in the gut and brain. Gastric emptying slows. |
| **Weeks 1-4** | Consistent and powerful appetite suppression. Noticeable weight loss of several pounds per week is common. Increased feelings of energy and well-being may be reported as metabolic function improves. | SLU-PP-332 begins to induce changes in muscle gene expression. Resting energy expenditure starts to increase. Insulin sensitivity improves. |
| **Months 1-3** | Significant and substantial weight loss. Improvements in metabolic markers (fasting glucose, HbA1c, lipids) become apparent in lab work. Clothing fits more loosely. | The body is in a sustained state of negative energy balance. Significant reduction in visceral and subcutaneous fat mass. |
| **Months 3-6+** | Achievement of target weight loss goals (often 15-20% of body weight). Long-term maintenance of metabolic health benefits. A new, lower body weight set point may be established. | The body has adapted to a new, healthier metabolic state with improved fuel partitioning and insulin sensitivity. |

### 4.2 Clinical Monitoring Recommendations

- **Metabolic Panel:** Baseline and periodic monitoring of weight, BMI, waist circumference, fasting glucose, HbA1c, and a lipid panel.
- **Thyroid Function:** As with all GLP-1 agonists, monitor for any signs or symptoms of thyroid nodules. A baseline thyroid exam is recommended.
- **GI Tolerance:** Assess for nausea, vomiting, or diarrhea, which are the most common side effects and may require dose adjustment.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Consistent daily timing is recommended to maintain steady-state plasma levels.
- **Optimization:** To mitigate GI side effects, consider starting with one capsule every other day for the first 1-2 weeks before escalating to daily use.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** A powerful metabolic formula that requires medical supervision, particularly due to the GLP-1 receptor agonist component.

### 5.1 Absolute Contraindications

- **Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).** (Class warning for all GLP-1 RAs).
- **History of Pancreatitis.**
- **Pregnancy and lactation.**

### 5.2 Relative Cautions

- **Gastroparesis:** GLP-1 RAs slow gastric emptying and can exacerbate this condition.
- **History of Gallbladder Disease.**

### 5.3 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Oral Medications** | Orforglipron | **Moderate Risk.** Orforglipron slows gastric emptying, which may delay or reduce the absorption of other oral drugs. Advise separating administration by at least 1 hour (for drugs needing rapid absorption) or monitoring for efficacy. |
| **Antidiabetic Agents** (e.g., Sulfonylureas, Insulin) | Orforglipron | **High Risk.** Increased risk of hypoglycemia. A dose reduction of the concomitant antidiabetic agent is likely required. Monitor blood glucose closely. |
| **Warfarin** | Orforglipron | **Low Risk.** Monitor INR more frequently upon initiation, as changes in gastric emptying could theoretically affect absorption. |

---

## 6. References

[1] Billon, C., et al. (2024). A pan-ERR agonist induces a thermogenic-like exercise-mimetic response in muscle. *Journal of Pharmacology and Experimental Therapeutics*, 388(2), 232-240. doi:10.1124/jpet.123.001850

[2] Wharton, S., et al. (2023). Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. *The New England Journal of Medicine*, 389(10), 877-888. doi:10.1056/NEJMoa2302392

[3] Lilly. (2023, June 23). *Lilly's phase 2 results published in The New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight* [Press release]. Retrieved from https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-results-published-new-england-journal-medicine

---


# Formula M-51: Advanced Exercise Mimetic & Body Composition Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Dual-pathway metabolic modulator & exercise mimetic – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **5-Amino-1MQ** | 50 mg | Nicotinamide N-Methyltransferase (NNMT) Inhibitor |
| **SLU-PP-332** | 1 mg | Pan-Agonist of Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to ensure optimal absorption and bioavailability of both components.

**Therapeutic Rationale & Intent:**
- Formula M-51 is engineered to replicate the metabolic and body composition benefits of physical exercise by simultaneously **inhibiting fat storage (5-Amino-1MQ)** and **increasing fat oxidation in muscle (SLU-PP-332)**.
- This formula creates a powerful "push-pull" effect on body fat, making it a highly effective agent for individuals seeking to improve body composition, enhance metabolic rate, and achieve the physiological benefits of exercise, particularly those who may be unable to engage in intense physical activity.

---

## 2. Deep Mechanism of Action

Formula M-51 integrates two powerful, synergistic metabolic modulators to reprogram cellular energy handling at the level of both fat and muscle tissue.

### 2.1 5-Amino-1MQ: NNMT Inhibition & Adipose Reprogramming

5-Amino-1MQ is a potent, membrane-permeable, small molecule inhibitor of Nicotinamide N-Methyltransferase (NNMT). NNMT is an enzyme highly expressed in adipose (fat) tissue that plays a key role in regulating cellular energy and metabolism. By inhibiting NNMT, 5-Amino-1MQ triggers a cascade of beneficial effects:
- **Increased NAD+ Levels:** NNMT consumes NAD+ in its reaction. Inhibiting it preserves and increases intracellular NAD+ levels, a critical coenzyme for mitochondrial function and sirtuin activity.
- **Reduced Fat Storage:** NNMT inhibition alters the metabolic programming of adipocytes, reducing their capacity to store fat and promoting the release of fatty acids.
- **Adipose Tissue "Browning":** It can induce a phenotype shift in white adipose tissue (WAT) towards a more metabolically active, thermogenic state similar to brown adipose tissue (BAT) [1].

### 2.2 SLU-PP-332: Pharmacological Exercise Mimicry in Muscle

SLU-PP-332 is a potent, orally bioavailable pan-agonist of the Estrogen-Related Receptors (ERRα, ERRβ, ERRγ). These nuclear receptors are master regulators of cellular energy metabolism, particularly in tissues with high energy demand like skeletal muscle. By activating these receptors, SLU-PP-332 induces a gene expression profile that closely mimics the effects of endurance exercise. This includes:
- **Increased Fatty Acid Oxidation:** Upregulation of genes involved in the transport and beta-oxidation of fatty acids, effectively reprogramming muscle to prefer fat as its primary fuel source.
- **Mitochondrial Biogenesis:** Increased expression of PGC-1α, the master regulator of mitochondrial creation, leading to more and healthier mitochondria.
- **Increased Resting Energy Expenditure:** Effectively "revving up" the metabolic engine of muscle to burn more calories, even at rest [2].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The profound efficacy of M-51 lies in its elegant "push-pull" synergy, creating a powerful and unidirectional flow of energy out of fat stores and into muscle for oxidation.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Adipose Tissue (The "Push")** | NNMT Inhibition & NAD+ Salvage | **5-Amino-1MQ** inhibits NNMT in fat cells. This blocks their ability to store fat and promotes the release of stored fatty acids into the bloodstream. It also increases cellular NAD+, enhancing metabolic rate. | A powerful mobilization of stored energy. Fat is actively "pushed" out of storage depots and made available for use as fuel. |
| **Muscle Tissue (The "Pull")** | ERR Agonism & Fuel Oxidation | **SLU-PP-332** activates ERR receptors in muscle, reprogramming it to preferentially take up and burn the fatty acids that 5-Amino-1MQ has released. It increases the muscle's metabolic machinery (mitochondria) to handle this increased fuel supply. | A powerful and specific utilization of the mobilized fat. The muscle tissue acts like a metabolic sink, actively "pulling" fat from the bloodstream and incinerating it for energy. |
| **Systemic (The Net Effect)** | Body Composition & Metabolism | The **"Push"** from 5-Amino-1MQ and the **"Pull"** from SLU-PP-332 work in perfect concert. Fat has nowhere to go but to be burned by muscle. | A rapid and significant reduction in fat mass, preservation of lean muscle, and a profound improvement in overall metabolic health, effectively mimicking the effects of a rigorous diet and exercise program. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Weeks 1-2** | An initial increase in energy levels and mental clarity. Some users report a mild thermogenic effect (feeling warmer) as metabolic rate increases. Appetite may be slightly reduced. | NNMT inhibition begins to increase NAD+ levels. Muscle gene expression starts to shift towards a fat-burning phenotype. |
| **Weeks 2-4** | Noticeable changes in body composition, even if weight on the scale doesn't change dramatically at first. A reduction in fat mass (e.g., waist circumference) and improved muscle definition are common. | Fatty acids are being mobilized from adipose tissue and oxidized in muscle at a significant rate. Mitochondrial density in muscle begins to increase. |
| **Months 1-3** | Significant reduction in body fat percentage and improvements in metabolic markers (lower triglycerides, improved insulin sensitivity). Increased endurance during physical activity. | The body has undergone a significant metabolic reprogramming. The fat-burning machinery is now highly efficient. |
| **Months 3-6+** | Achievement of body composition goals. A sustained state of high energy and metabolic efficiency. Long-term maintenance of a healthier, leaner physique. | A new, healthier metabolic set point is established, making it easier to maintain a lean body composition. |

### 4.2 Clinical Monitoring Recommendations

- **Body Composition:** Use of DEXA scan or bioimpedance analysis (e.g., InBody) at baseline and every 2-3 months to track changes in fat mass, lean mass, and body fat percentage.
- **Metabolic Panel:** Baseline and periodic monitoring of a lipid panel (triglycerides, HDL, LDL) and markers of insulin sensitivity (fasting glucose, insulin, HbA1c).
- **Energy Levels:** Subjective tracking of energy levels, endurance, and recovery from exercise.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Morning administration is often preferred to align with the body's natural metabolic rhythm.
- **Optimization:** The effects of M-51 are significantly amplified when combined with a healthy, calorie-controlled diet and a regular exercise program (particularly resistance training to maximize muscle preservation).

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Both 5-Amino-1MQ and SLU-PP-332 are novel research compounds. Both have demonstrated favorable safety profiles in extensive preclinical studies with no significant adverse effects reported.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity.
- **Tolerability:** Generally expected to be very well-tolerated based on preclinical data.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **N/A** | 5-Amino-1MQ, SLU-PP-332 | No significant drug interactions have been identified in preclinical studies. However, as these are novel compounds, caution is advised when co-administering with other medications until human data becomes available. Particular attention should be paid to other metabolic agents. |

---

## 6. References

[1] Neelakantan, H., et al. (2019). The small molecule NNMT inhibitor, 5-amino-1MQ, reverses diet-induced obesity, insulin resistance and fatty liver disease. *Biochemical Pharmacology*, 167, 103-113. doi:10.1016/j.bcp.2019.03.018

[2] Billon, C., et al. (2024). A pan-ERR agonist induces a thermogenic-like exercise-mimetic response in muscle. *Journal of Pharmacology and Experimental Therapeutics*, 388(2), 232-240. doi:10.1124/jpet.123.001850

---


# Formula M-2531: Advanced Mitochondrial & Metabolic Support Protocol

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Dual-pathway mitochondrial and metabolic modulator – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **MOTS-c** | 10 mg | Mitochondrial-Derived Peptide; AMPK Activator; Myostatin Inhibitor |
| **NAD+ (Nicotinamide Adenine Dinucleotide)** | 50 mg | Essential Coenzyme; Sirtuin Activator; Redox Agent |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to ensure optimal absorption and bioavailability of both the peptide and the coenzyme.

**Therapeutic Rationale & Intent:**
- Formula M-2531 is engineered to enhance mitochondrial function, improve metabolic health, and support cellular energy production by combining a key **mitochondrial signaling peptide (MOTS-c)** with an **essential metabolic coenzyme (NAD+)**.
- This formula is designed to combat age-related metabolic decline, improve insulin sensitivity, preserve lean muscle mass, and enhance physical performance by addressing the very foundation of cellular energy.

---

## 2. Deep Mechanism of Action

Formula M-2531 integrates two fundamental and highly synergistic components of cellular energy metabolism to create a powerful health-promoting effect.

### 2.1 MOTS-c: The Mitochondrial-Derived Exercise Mimetic

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a unique peptide encoded within the mitochondrial genome that acts as a systemic metabolic regulator, particularly under conditions of stress. Its levels increase with exercise, and it functions as a "mitokine," signaling from the mitochondria to the rest of the cell and body. Its key actions include:
- **AMPK Activation:** MOTS-c is a potent activator of AMP-activated protein kinase (AMPK), a master switch for cellular energy homeostasis. AMPK activation promotes fatty acid oxidation, enhances glucose uptake into muscle, and inhibits anabolic processes, effectively mimicking the metabolic state of exercise [1, 2].
- **Myostatin Inhibition:** MOTS-c has been shown to reduce the expression of myostatin, a powerful negative regulator of muscle growth. This action helps to prevent sarcopenia (age-related muscle loss) and preserve lean muscle mass, which is critical for maintaining metabolic rate [4].
- **Improved Insulin Sensitivity:** By enhancing glucose uptake and utilization in peripheral tissues, MOTS-c directly combats insulin resistance [3].

### 2.2 NAD+: The Fundamental Coenzyme of Life

Nicotinamide Adenine Dinucleotide (NAD+) is a critical coenzyme found in every cell, essential for hundreds of enzymatic reactions. Its roles are central to life:
- **Mitochondrial Respiration:** NAD+ is a primary electron carrier in the electron transport chain, essential for the production of ATP, the body's energy currency.
- **Sirtuin Activation:** NAD+ is the sole substrate for sirtuins (e.g., SIRT1, SIRT3), a family of proteins that act as master regulators of cellular health, DNA repair, inflammation, and longevity [5].
- **PARP Activation:** It is also required for Poly (ADP-ribose) polymerases (PARPs), enzymes critical for repairing DNA damage.
- **Age-Related Decline:** Cellular NAD+ levels decline significantly with age, which is considered a key driver of the aging process and age-related diseases.

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The synergy between MOTS-c and NAD+ is one of the most fundamental and powerful in metabolic medicine. It is a classic "Signal & Fuel" paradigm.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Signaling (The "Signal")** | AMPK Activation & Myostatin Inhibition | **MOTS-c** acts as the primary signal, telling the cell to enter an "exercise" state: burn more fat, take up more glucose, and preserve muscle. It effectively turns on the metabolic machinery. | A powerful, systemic shift towards a healthier, more youthful metabolic profile. The body is programmed to handle fuel more efficiently and maintain its functional tissue. |
| **Fuel (The "Fuel")** | NAD+ Biosynthesis & Redox Balance | **NAD+** provides the essential coenzyme required to execute the metabolic program initiated by MOTS-c. The increased fatty acid oxidation and glucose metabolism demanded by MOTS-c cannot happen without sufficient NAD+. It also fuels the sirtuin activity that enhances mitochondrial function. | The metabolic machinery switched on by MOTS-c is given the high-octane fuel it needs to run at peak performance. Without adequate NAD+, the MOTS-c signal would be ineffective. |
| **Systemic (The Net Effect)** | Metabolic & Muscular Health | The **"Signal"** from MOTS-c and the **"Fuel"** from NAD+ work in a perfect positive feedback loop. MOTS-c signals for more metabolic activity, which requires NAD+. The increased NAD+ then enhances the very mitochondrial processes that MOTS-c regulates. | A profound and comprehensive rejuvenation of cellular metabolism. This leads to improved insulin sensitivity, better body composition, enhanced physical performance, and activation of longevity pathways. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Weeks 1-2** | An initial increase in baseline energy levels and a feeling of improved stamina during physical activity. Recovery from exercise may feel faster. | Cellular NAD+ levels begin to replete. MOTS-c starts to activate AMPK in muscle and other tissues. |
| **Weeks 2-4** | More consistent energy throughout the day. Noticeable improvements in exercise capacity and endurance. Some users report better blood sugar control and reduced cravings. | Mitochondrial biogenesis is initiated. Insulin sensitivity begins to improve at the cellular level. Myostatin levels may start to decrease. |
| **Months 1-3** | Significant improvements in physical performance, body composition (less fat, more muscle), and overall well-being. Lab markers for metabolic health (glucose, insulin, lipids) show improvement. | The body has undergone a significant improvement in its metabolic flexibility and efficiency. Sirtuin and PARP activity is enhanced. |
| **Months 3-6+** | A new, higher baseline for physical and mental energy is established. Enhanced resilience to metabolic stressors. Long-term benefits for healthy aging are being accrued. | A sustained state of optimized mitochondrial function and metabolic health. |

### 4.2 Clinical Monitoring Recommendations

- **Metabolic Panel:** Baseline and periodic monitoring of fasting glucose, insulin, HbA1c, and a lipid panel to track improvements in metabolic health.
- **Body Composition:** Use of DEXA or bioimpedance to track changes in lean muscle mass and fat mass.
- **Physical Performance:** Objective measures like VO2 max testing, grip strength, or timed walk tests can quantify improvements in physical function.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Morning administration is often preferred to align with the body's natural energy cycle.
- **Optimization:** The benefits of M-2531 are dramatically amplified when combined with a consistent exercise program. The formula primes the body to respond more robustly to the stimulus of exercise.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Excellent safety profile. Both MOTS-c and NAD+ are endogenous molecules naturally present in the human body. The doses used are physiological and designed to restore youthful levels.
- **Absolute Contraindications:** Pregnancy and lactation; known hypersensitivity.
- **Tolerability:** Generally very well-tolerated with no significant adverse effects reported in preclinical or early human studies.

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Antidiabetic Agents** (e.g., Metformin, Insulin) | MOTS-c, NAD+ | **Low to Moderate Risk.** The formula's powerful effects on insulin sensitivity may increase the risk of hypoglycemia. Patients on antidiabetic medications should monitor their blood glucose closely, and a dose reduction of their other medications may be necessary under medical supervision. |
| **Cancer Therapies** | NAD+ | **Theoretical Risk.** Some cancer cells have high NAD+ requirements. While evidence is mixed and context-dependent, it is prudent to avoid high-dose NAD+ supplementation during active cancer treatment unless specifically cleared by an oncologist. |

---

## 6. References

[1] Reynolds, J. C., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. *Nature Communications*, 12(1), 470. doi:10.1038/s41467-020-20790-0

[2] Lee, C., et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. *Cell Metabolism*, 21(3), 443-454. doi:10.1016/j.cmet.2015.02.009

[3] Zong, H., et al. (2016). The regulation of MOTS-c in the development of insulin resistance. *Journal of Cellular and Molecular Medicine*, 20(8), 1437-1447. doi:10.1111/jcmm.12844

[4] Kong, X., et al. (2021). MOTS-c reduces myostatin and muscle atrophy signaling. *American Journal of Physiology-Endocrinology and Metabolism*, 320(4), E716-E727. doi:10.1152/ajpendo.00624.2020

[5] Johnson, S., & Imai, S. I. (2018). NAD+ biosynthesis, aging, and disease. *F1000Research*, 7, 132. doi:10.12688/f1000research.12922.1

---


# Formula RG-5555: Advanced Multi-Peptide Healing & Recovery Blend

**PHYSICIAN USE ONLY | RESEARCH PEPTIDES**

*Last Updated: February 5, 2026*

---

## 1. Composition & Therapeutic Overview

**Formula Classification:** Multi-pathway regenerative and anti-inflammatory protocol – enteric-coated research capsule designed for physician-directed use only.

**Per Capsule Composition:**

| Component | Dosage | Primary Mechanism of Action |
|---|---|---|
| **BPC-157** | 500 mcg | Systemic Tissue Repair; Angiogenesis Modulator; VEGF/NO Pathway |
| **TB-500 (Ac-SDKP)** | 500 mcg | Actin Sequestration; Cellular Migration & Differentiation |
| **KPV** | 500 mcg | Potent Anti-Inflammatory; NF-κB Inhibition |
| **Larazotide** | 500 mcg | Zonulin Antagonist; Gut Barrier Restoration |

**Delivery System:**
- Enteric-coated oral capsule for daily use, designed to protect peptide integrity and ensure optimal absorption for systemic effects.

**Therapeutic Rationale & Intent:**
- Formula RG-5555 is engineered to provide a comprehensive, multi-system healing and recovery solution by simultaneously targeting four critical pathways: **systemic inflammation (Larazotide)**, **local inflammation (KPV)**, **cellular migration (TB-500)**, and **tissue regeneration (BPC-157)**.
- This formula is designed to create an optimal healing environment, from the gut to the site of injury, for accelerated recovery from injury, surgery, and chronic inflammatory states.

---

## 2. Deep Mechanism of Action

Formula RG-5555 integrates four synergistic peptides that together orchestrate a powerful, multi-faceted healing response, addressing the root causes of poor recovery.

### 2.1 Larazotide: Foundational – Gut Barrier Restoration

Larazotide is a synthetic peptide that acts as a zonulin antagonist. Zonulin is a protein that reversibly regulates intestinal permeability. In many inflammatory states, zonulin levels are elevated, leading to the breakdown of tight junctions between intestinal cells (a "leaky gut"). This allows bacterial endotoxins (LPS) and undigested food particles to enter the bloodstream, triggering a state of chronic, low-grade systemic inflammation. By blocking zonulin, Larazotide restores the integrity of the intestinal barrier, effectively shutting off this primary source of systemic inflammation [4].

### 2.2 KPV: Local – Potent Anti-Inflammatory Action

KPV is the C-terminal fragment of α-MSH and is one of the most potent anti-inflammatory peptides known. It acts intracellularly to inhibit the activation of Nuclear Factor-kappa B (NF-κB), a master regulator of the inflammatory response. By preventing NF-κB from entering the nucleus, KPV effectively shuts down the transcription and production of numerous pro-inflammatory cytokines (e.g., TNF-α, IL-1β, IL-6) directly at the site of injury or inflammation [3].

### 2.3 TB-500 (as Ac-SDKP): Cellular Migration & Differentiation

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring peptide that plays a key role in tissue repair. Its primary mechanism is to sequester actin monomers, promoting the rapid polymerization of the actin cytoskeleton, which is essential for cell motility. This action promotes the migration of stem cells, endothelial cells, and keratinocytes to the site of injury. It also has anti-inflammatory properties and promotes angiogenesis, creating a favorable environment for healing [2].

### 2.4 BPC-157: Systemic Tissue Repair & Angiogenesis

BPC-157 (Body Protective Compound) is a pentadecapeptide with extraordinary regenerative capabilities. It is believed to be a master healing peptide that modulates the activity of numerous growth factors (e.g., VEGF, EGF) and signaling pathways. It potently promotes angiogenesis (the formation of new blood vessels), which is critical for delivering oxygen and nutrients to damaged tissue. It also accelerates the repair of tendon, ligament, muscle, bone, and nervous tissue, and has been shown to counteract the catabolic effects of corticosteroids [1].

---

## 3. Synergistic Architecture: A Multi-Level Analysis

The synergy of RG-5555 is based on a logical, four-step process that creates the ideal cascade for healing.

| Level | Primary Pathway | Key Components & Interactions | Integrated Clinical Effect |
|---|---|---|---|
| **Step 1: Quell Systemic Fire** | Gut Barrier Integrity | **Larazotide** seals the gut lining, dramatically reducing the systemic inflammatory burden from LPS and other endotoxins. | Creates a calm, low-inflammation systemic environment, freeing up the immune system to focus on targeted repair instead of fighting a low-grade, body-wide war. |
| **Step 2: Extinguish Local Fire** | Anti-inflammation | **KPV** enters the inflamed cells at the site of injury and shuts down the NF-κB inflammatory signaling cascade. | The local environment is cleared of destructive pro-inflammatory cytokines, reducing pain, swelling, and secondary tissue damage. |
| **Step 3: Call in the Workers** | Cell Migration | **TB-500** acts as a homing signal, recruiting stem cells, endothelial cells, and other repair cells to the now-prepared, low-inflammation injury site. | The necessary cellular building blocks for repair are rapidly delivered to the precise location where they are needed. |
| **Step 4: Rebuild the Structure** | Angiogenesis & Regeneration | **BPC-157** orchestrates the final phase, stimulating the formation of new blood vessels to supply the site and directly promoting the regeneration of the damaged tissue itself. | A rapid and robust reconstruction of damaged tendons, ligaments, muscle, and other tissues, leading to a functionally superior and faster recovery. |

---

## 4. Comprehensive Patient & Physician Guide

### 4.1 Detailed Patient Expectations & Timeline

| Timeframe | Subjective Experience | Physiological Changes |
|---|---|---|
| **Days 1-7** | An initial reduction in generalized aches and pains, and improved digestive comfort. Localized pain and swelling at an injury site may begin to decrease. | Larazotide begins to restore gut barrier function. KPV starts to reduce local and systemic inflammation. |
| **Weeks 1-2** | Significant improvement in recovery from exercise or minor injuries. A noticeable reduction in inflammation and pain in chronic conditions (e.g., arthritis, tendonitis). | TB-500 enhances cellular migration to injury sites. The overall inflammatory load is significantly reduced. |
| **Weeks 2-4** | Accelerated healing of acute injuries with measurable improvements in function, range of motion, and strength. Post-surgical wounds heal faster with less scarring. | BPC-157-driven angiogenesis and tissue regeneration are in full effect. New, healthy tissue is being actively laid down. |
| **Months 1-3** | Substantial to complete resolution of many acute injuries. Significant functional improvement and pain reduction in chronic inflammatory and degenerative conditions. | The healed tissue is remodeled and strengthened. The body's systemic inflammatory state is reset to a healthier baseline. |

### 4.2 Clinical Monitoring Recommendations

- **Inflammatory Markers:** Baseline and periodic monitoring of hs-CRP and ESR can objectively track the reduction in systemic inflammation.
- **Functional Assessment:** For specific injuries, use objective measures of range of motion, strength, and function to track progress.
- **GI Health:** Subjective tracking of digestive symptoms. For complex cases, a zonulin or LPS test can be used to assess gut barrier function.

### 4.3 Dosing & Administration

- **Standard Dose:** One capsule daily.
- **Timing:** Can be taken with or without food. Consistent daily timing is recommended.
- **Optimization:** The benefits are maximized when combined with a nutrient-dense, anti-inflammatory diet (e.g., low in processed foods and sugar) and appropriate physical therapy or rehabilitation for the specific injury.

---

## 5. Safety & Drug Interaction Profile

- **Overall:** Excellent safety profile. All four peptides are well-tolerated with extensive preclinical and/or clinical data supporting their safety.
- **Absolute Contraindications:** 
  - **Active Malignancy:** Due to the potent angiogenic effects of BPC-157 and TB-500, this formula should not be used in patients with active cancer.
  - **Pregnancy and lactation.**

### 5.1 Drug Interaction Matrix

| Drug/Class | Interacting Component(s) | Clinical Consideration & Management |
|---|---|---|
| **Immunosuppressants** (e.g., Corticosteroids, Methotrexate) | BPC-157, TB-500, KPV | **Moderate Risk.** The pro-healing and immunomodulatory effects of the peptides may compete with or alter the effects of immunosuppressive therapy. Use requires close medical supervision. BPC-157 may counteract the catabolic effects of corticosteroids. |
| **Anticoagulants** (e.g., Warfarin, DOACs) | BPC-157, TB-500 | **Theoretical Risk.** As potent promoters of angiogenesis and wound healing, there is a theoretical risk of altering bleeding or clotting dynamics. Monitor closely, especially in the peri-operative period. |
| **Anti-hypertensives** | BPC-157 | **Low Risk.** BPC-157 may have a mild, modulating effect on blood pressure via the nitric oxide system. Monitor BP upon initiation. |

---

## 6. References

[1] Seiwerth, S., et al. (2018). BPC 157 and Standard Angiogenic Growth Factors. *Current Pharmaceutical Design*, 24(18), 1958-1967. doi:10.2174/1381612824666180709110245

[2] Goldstein, A. L., & Klein, E. (2015). Thymosin β4: a multi-functional regenerative peptide. *Annals of the New York Academy of Sciences*, 1349(1), 27-34. doi:10.1111/nyas.12795

[3] Brzoska, T., et al. (2008). The tridecapeptide K(D)PT and its C-terminal tripeptide KPV exert potent anti-inflammatory effects in vitro and in vivo. *Journal of Investigative Dermatology*, 128(3), 644-652. doi:10.1038/sj.jid.5701091

[4] Leffler, D. A., et al. (2017). Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial. *Gastroenterology*, 152(5), 1090-1099.e13. doi:10.1053/j.gastro.2016.12.041
